Editor's Note: This video was filmed on May 7th.

Corcept Therapeutics (NASDAQ:CORT) shares were slammed last week after a phase 3 trial for mifepristone to treat patients with depression was stopped after an independent data monitoring committee indicated that the drug would probably not provide a statistically significant benefit to currently enrolled patients. The data was from 266 patients in a study that was intended to expand up to 450 patients, but instead of sinking more money into the study by continuing, Corcept's management decided to end the trial and focus on other potential indications.

Indications as diverse as breast cancer, post-traumatic stress disorder, and alcohol dependence.

What to make of this diversity? Does it signify a management that is scattershotting?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give you their answer and their thoughts on the company.

Looking for a potentially better option? Try this top stock on for size.
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David WilliamsonMichael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.